Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36547665.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elía et al., p. 866.
Medical subject headings
- Mifepristone
- Breast Neoplasms